Proyecto De Biomedicina Cima, S.l.

Fundacion Para La Investigacion Medica Aplicada

Advanced Marker Discovery, S.l.

Daniel Ajona Martínez-Polo

Rubén Pío Osés

Luis Montuenga Badía

Leticia Corrales Pecino

María José Pajares Villandiego

Jackeline Agorreta Arrazubi

María Josefa Pajares Villandiego

The invention provides a method of diagnosis and/or prognosis of lung cancer, the method comprising the steps of: (a) determining the level of a C4 activation fragment in a test sample, and (b) comparing the level of the test sample with the level of a C4 activation fragment detected in a control sample, wherein if the level of C4 activation fragment is higher than the level in a reference control, it is indicative that the subject suffers lung cancer or has a bad prognosis. The present invention further provides methods for determining the risk of suffering from lung cancer as well as for deciding whether to initiate a medical regimen and to determine the efficacy of said medical regimen, based on the determination of a C4 activation fragment. C4 activation fragment, used as marker, confers high sensitivity and specificity to the methods object of the invention.

Lung cancer molecular markers

Growing community of inventors

Pamplona, Spain

Daniel Ajona Martínez-Polo